Stocks To Watch Today: Paras Defence, Glenmark Pharma, Gensol Engineering, Ola Electric
Senores Pharmaceuticals Ltd., Paras Defence and Space Technologies Ltd., Kalyani Steels Ltd. and Glenmark Pharmaceuticals Ltd. are set to see action going into trade on Tuesday.
Senores Pharmaceuticals: The company signed an agreement with Wockhardt to acquire USFDA-approved Topiramate tablets, used to treat epilepsy and migraine. The market size of Topiramate Tablet in the US was $111.47 million.
Paras Defence and Space Technologies: The company signed an MoU with Israel-based Heven Drones to create new opportunities and expand both parties' business in the defence sector. The parties intend to form a JV company in India for the development and production of logistics to support the MoU.
Kalyani Steels: The company reappointed RK Goyal as Managing Director effective Jan. 17, 2026.
Glenmark Pharmaceuticals: Ichnos Glenmark Innovation received USFDA fast-track status for ISB 2001, used to treat adult patients with relapsed or refractory multiple myeloma.
Oil and Natural Gas Corp: The company completed the offshore facilities decommissioning project along with Reliance Industries and Shell.
Gensol Engineering: The company clarified that the Delhi High Court order related to the Orix Leasing case is only an ex parte interim order, and the company is seeking legal assistance regarding this court order. This clarification is in response to reports stating that the High Court has barred the company and BluSmart from transferring electric vehicles leased by Orix to any third party.
Ola Electric Mobility: The company clarified that it holds a perpetual, royalty-free licence to use certain licensed intellectual property, including the logo, and that this licence has been granted exclusively in relation to the company's electric vehicle business and is valid globally.
Ircon International: The company received an order worth Rs 187 crore from Kerala State IT Infrastructure for the construction of a dedicated rural industrial park in Thiruvananthapuram.
RateGain Travel Technologies: The company appointed Rohan Mittal as CFO effective May 6.
Ceigall India: Ceigall India has entered into an agreement with the National Highways Authority of India to develop a six-lane bypass road. The project is valued at Rs 1,064 crore.
Post-Market Earnings
Computer Age Management Services Q4 Highlights (Consolidated, QoQ)
Revenue down 3.68% at Rs 356 crore versus Rs 370 crore (Bloomberg estimate: Rs 364 crore)
EBIT down 11% at Rs 136 crore versus Rs 153 crore (Bloomberg estimate: Rs 166 crore)
EBIT Margin at 38.3% versus 41.5% (Bloomberg estimate: 45.7%)
Net Profit down 9% at Rs 114 crore versus Rs 125.5 crore (Bloomberg estimate: Rs 117 crore).
Coforge Q4 Highlights (Consolidated, QoQ)
Revenue up 4.6% to Rs 3,409 crore versus Rs 3,258 crore (Bloomberg estimate: Rs 3,527 crore)
EBIT up 26% at Rs 401 crore versus Rs 318 crore (Bloomberg estimate: Rs 584 crore)
EBIT margin at 11.8% versus 9.8% (Bloomberg estimate: 16.6%)
Net Profit up 21% to Rs 261.2 crore versus Rs 215.5 crore (Bloomberg estimate: Rs 282.4 crore)
Fixes June 4 as a record date for splitting each share into 2.
Expect robust growth FY26 despite macroeconomic uncertainty
Expect growth in FY26 to come from multiple quadrants
Demand outlook has worsened for travel industry
Indian Hotels Q4 Highlights (Consolidated, YoY)
Revenue up 27.3% to Rs 2,425 crore versus Rs 1,905 crore (Bloomberg estimate: Rs 2,418.5 crore)
Ebitda up 30% to Rs 857 crore versus Rs 659 crore (Bloomberg estimate: Rs 874 crore)
Margin at 35.3% versus 34.6% (Bloomberg estimate: 36.1%)
Net Profit up 25% to Rs 522 crore versus Rs 553.4 crore (Bloomberg estimate: Rs 553 crore)
In 2026, Company plans to invest Rs 1,200 crore on asset upgrades, new projects, the Taj Brand and Digital Tools.
Aims for double-digit revenue growth led by strong same-store sales, new business and 30 hotel openings.
Sector outlook remains strong, with demand outpacing supply, a recovery of foreign tourist arrivals and steady momentum across leisure, social and MICE segments.
CCL Products Q4 Highlights (Consolidated, YoY)
Revenue up 15% to Rs 836 crore versus Rs 727 crore (Bloomberg estimate: Rs 827 crore)
Ebitda up 38.2% at Rs 163 crore versus Rs 118 crore (Bloomberg estimate: Rs 130 crore)
Margin at 19.5% versus 16.2% (Bloomberg estimate: 15.7%)
Net Profit up 56% to Rs 102 crore versus Rs 65.2 crore (Bloomberg estimate: Rs 68 crore)
Cigniti Technologies Q4 Highlights (Consolidated, QoQ)
Revenue up 2.7% to Rs 530.3 crore versus Rs 516.4 crore
EBIT up 5% to Rs 81.2 crore versus Rs 77 crore
Margin at 15.3% versus 14.9%
Net Profit up 15% to Rs 73 crore versus Rs 63.5 crore.
Pratap Snacks Q4 (Consolidated, YoY)
Revenue up 3.1% at Rs 398 crore versus Rs 386 crore.
Ebitda down 94.38% at Rs 1.85 crore versus Rs 32.93 crore.
Ebitda at 0.46% versus 8.53%.
Net loss at Rs 12 crore versus profit of Rs 12 crore.
DCM Shriram Q4 Highlights (Consolidated, YoY)
Revenue up 20% at Rs 2,876 crore versus Rs 2,399 crore
Ebitda up 52.8% at Rs 405 crore versus Rs 265 crore
Margin at 14% versus 11%
Net profit up 52% at Rs 179 crore versus Rs 118 crore
J&K Bank Q4 Highlights (Standalone, YoY)
Net interest income up 13% at Rs 1,480 crore versus Rs 1,306 crore.
Net profit down 8.5% at Rs 584 crore versus Rs 639 crore
Operating Profit up 20.5% at Rs 800 crore versus Rs 664 crore
Gross NPA at 3.37% versus 4.08% (QoQ)
Net NPA at 0.79% versus 0.94% (QoQ)
Earnings In Focus
Aadhar Housing Finance, Aarti Drugs, Alembic Pharmaceuticals, Aptus Value Housing Finance India, Avalon Technologies, Bank of Baroda, CG Power and Industrial Solutions, eMudhra, Godrej Consumer Products, Hindustan Petroleum Corporation, JBM Auto, Kajaria Ceramics, Kansai Nerolac Paints, KEI Industries, Vedant Fashions, Mahanagar Gas, Paradeep Phosphates, One 97 Communications, Piramal Enterprises, Polycab India, Poly Medicure, Quick Heal Technologies, Radico Khaitan, Safari Industries India, Shipping Corporation of India Land and Assets and Sundaram-Clayton.
-
Getting To Work Costs Women More | The Reason Why
It is not just about women paying more than men. It is about women paying much more in cities than in villages.
-
AI Bias In Investing Cannot Be Eliminated, But It Can Be Governed
Framing is a particularly important example as identical financial information presented in terms of gains rather than losses can lead an LLM to reach a different assessment.
-
Joining The Dots | Dark Skies, Steady Diya: Why Hope Holds This Diwali
With war, a weak rupee and foreign outflows weighing on sentiment, policymakers at the NDTV World Summit and market veterans at NDTV Profit Ignite: Diwali Edition offered the same advice: stay invested and filter out the noise.
-
The Curious Case of Equitas Small Finance Bank And A CEO Who Quit For Stock
PN Vasudevan believes persistent investor concerns over a perceived conflict of interest had become a governance overhang on Equitas Small Finance Bank's stock, even as the lender improved profitability and asset quality.
-
Talking Points This Week: AI Cash Burn, A Tiger Comeback And An India That Still Finds Its Own Path
India is not immune to higher oil or tighter global liquidity, yet its earnings base is broader, its domestic policy levers are still available.
-
Foreign Investors Own Half Of HDFC Bank and ICICI Bank. An LTCG Cut Could Matter Most Here
Foreign portfolio investors have US$115 billion parked in HDFC Bank, ICICI Bank. If the government cuts long-term capital gains tax, Jefferies says returning foreign money could land here first.
-
'Never Seen This Level Of Negativity': Sandeep Tandon Says The Next Rally May Be Closer Than You Think
Veteran investor Sandeep Tandon says foreign selling is easing, large-caps are due a comeback and mid-caps are crowded, while he turns positive on gold, power and pharma this Diwali.
-
Indians Stay With Family, Not In Hotels | The Reason Why
India still lacks enough clean, reliable and affordable hotels for budget-conscious travellers.
-
The Economic Imperative: Analysing The Material Driving Force Behind India-Canada Strategic Reset
This economic complementarity is further reinforced by deep institutional investment ties and talent mobility, which form the bedrock of the bilateral framework.
-
Medicine Pricing: Where Must Profit Stop?
India must confront excessive margins, hidden incentives and regulatory gaps that threaten the integrity of medicine.